Detalhe da pesquisa
1.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun;
135: 102984, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36621174
2.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis;
23(1): 332, 2023 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37198536
3.
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis;
81(12): 1757-1766, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36357161
4.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis;
82(6): 883-885, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36720583
5.
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Lancet Rheumatol;
4(6): e417-e429, 2022 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35527808
6.
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
Lancet Rheumatol;
4(5): e338-e350, 2022 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35317410